Market conditions remain favorable despite a general slowdown in the biopharma-segment as result of economic uncertainties, inflation and increasing interest rates which have had a negative effect on access to capital—especially for small and medium-sized companies.

“The first quarter of 2023 has been our strongest Q1 ever and I am happy with the company’s development which continues according to plan.

Sales revenue has grown steadily during the quarter, and we have had an excellent growth in backlog. Average order value has also increased by 65%.

This is evidence that we now have a more established relationship with our customers, and that they are including Bio-Works in a longer planning horizon,” says Jonathan Royce, CEO at Bio-Works.

Sales revenue growth has been driven by a good development in the European market, while the growth in the order book has come primarily from the North American market.

During the quarter, Bio-Works has also successfully hosted several audits of the company’s quality system. These audits have been performed by both customers and external auditors.

“I have a positive outlook for 2023. Many suppliers to biopharma have reported lower demand after the pandemic, but this is not a factor that we believe is going to affect Bio-Works. Our prepacked product series, GoBio, is developing better than expectations and we are planning to launch a new product later this year focused on the gene therapy and oligonucleotide markets, two segments where we see a strong potential for high growth.

At the same time, our customers continue to give Bio-Works high marks, which puts us in a strong position to continue to grow and reach profitability as planned,” says Royce.

The company’s plan to reach breakeven 2024 remains. At the end of the quarter, bank balances amounted to 51.4 MSEK.